Pharmacokinetic and pharmacodynamic characterization of CD8-targeted lentiviral vector for in vivo CD19-directed CAR-T therapy.
In-vivo CAR-T generation without expensive manufacturing could democratize cell therapy access for cancer patients worldwide.
This study characterizes the pharmacokinetics and pharmacodynamics of a CD8-targeted lentiviral vector that directly transduces T cells in vivo to express a CD19-directed CAR, representing a potential manufacturing-free approach to CAR-T therapy. In vivo CAR-T generation could dramatically reduce the cost, time, and infrastructure barriers associated with current ex vivo CAR-T manufacturing.
What the study was
- Study design
- Preclinical pharmacokinetic/pharmacodynamic characterization
- Population
- Mouse models for in vivo CAR-T generation via CD8-targeted lentiviral vector
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Molecular therapy. Advances
Why it surfaced
In vivo CAR-T generation via lentiviral vector is a paradigm-shifting approach that could eliminate the manufacturing bottleneck for CAR-T therapy. Score capped at 5 (non-human study rule), but NOVEL_TREATMENT flag applied for exceptional innovation potential. PMC full text available.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.